These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 17846007)

  • 61. [New medications; bevacizumab].
    Cohen AF; van Bronswijk H
    Ned Tijdschr Geneeskd; 2006 Oct; 150(40):2194-5. PubMed ID: 17061430
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Role of angiogenesis inhibitors in the treatment of colorectal cancer].
    Bodoky G
    Magy Onkol; 2007; 51(2):139-44. PubMed ID: 17660870
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical experience with bevacizumab in colorectal cancer.
    Salesi N; Bossone G; Veltri E; Di Cocco B; Marolla P; Pacetti U; Larosa G; Muni R; Vecchione A
    Anticancer Res; 2005; 25(5):3619-23. PubMed ID: 16101190
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Angiogenesis targeting in gastro-intestinal cancers].
    Meric JB
    Bull Cancer; 2007; 94(7 Suppl):F207-15. PubMed ID: 17964998
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Therapeutic strategies using VEGF inhibitors in colorectal cancer].
    Boige V; Malka D; Ducreux M
    Bull Cancer; 2005 Aug; 92(Spec no):S29-36. PubMed ID: 16387667
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Future directions in the use of antiangiogenic agents in patients with colorectal cancer.
    Hoff PM
    Semin Oncol; 2004 Dec; 31(6 Suppl 17):17-21. PubMed ID: 15696026
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The role of bevacizumab in colorectal cancer: understanding its benefits and limitations.
    Mulder K; Scarfe A; Chua N; Spratlin J
    Expert Opin Biol Ther; 2011 Mar; 11(3):405-13. PubMed ID: 21281258
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bevacizumab in the treatment of breast cancer.
    Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP
    Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Experience with bevacizumab in the management of epithelial ovarian cancer.
    Burger RA
    J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Bevacizumab. Progress in cancer therapy by antiangiogenesis].
    Krämer I; Lipp HP
    Med Monatsschr Pharm; 2006 Jul; 29(7):249-54; quiz 255-6. PubMed ID: 16866078
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer.
    Ellis LM
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S1-7. PubMed ID: 17145519
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Targeted agents to improve treatment results in colon cancer: bevacizumab and cetuximab.
    Klein B; Gottfried M
    J BUON; 2007 Sep; 12 Suppl 1():S127-36. PubMed ID: 17935270
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Targeted agents for adjuvant therapy of colon cancer.
    Saif MW
    Clin Colorectal Cancer; 2006 May; 6(1):46-51. PubMed ID: 16796791
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Bevacizumab for advanced breast cancer.
    Traina TA; Rugo HS; Dickler M
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):303-19. PubMed ID: 17512451
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
    Reinacher-Schick A; Pohl M; Schmiegel W
    Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):250-67. PubMed ID: 18382435
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Safety of bevacizumab with fluoropyrimidine-based regimens for first-line treatment of metastatic colorectal cancer.
    Tyagi P
    Clin Colorectal Cancer; 2006 Sep; 6(3):189-91. PubMed ID: 17026787
    [No Abstract]   [Full Text] [Related]  

  • 77. Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).
    Wilson PM; Yang D; Azuma M; Shi MM; Danenberg KD; Lebwohl D; Sherrod A; Ladner RD; Zhang W; Danenberg PV; Trarbach T; Folprecht G; Meinhardt G; Lenz HJ
    Pharmacogenomics J; 2013 Oct; 13(5):410-6. PubMed ID: 22664478
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Incidence and management of bevacizumab-related toxicities in colorectal cancer.
    Saif MW; Mehra R
    Expert Opin Drug Saf; 2006 Jul; 5(4):553-66. PubMed ID: 16774493
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Anti-angiogenic treatment of gastrointestinal malignancies.
    Salmon JS; Lockhart AC; Berlin J
    Cancer Invest; 2005; 23(8):712-26. PubMed ID: 16377590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.